Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc.
- Market cap
- $3.30B
Your view on ELVN
Overview
What the company does, where it operates, and who runs it.
About Enliven Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard A. Fair
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard A. Fair
- Headquarters
- US
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Enliven Therapeutics, Inc.. Starting points for Enliven Therapeutics, Inc.: EPS -$1.46, beta 0.24 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Enliven Therapeutics, Inc.. Trailing twelve-month EPS for Enliven Therapeutics, Inc. stands at -$1.46. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$76.29
average of 7 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy6
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | −$0.44 | −$0.44 | −$1.68 | −$2.03 |
| Low estimate | −$0.58 | −$0.50 | −$2.02 | −$2.44 |
| High estimate | −$0.39 | −$0.41 | −$1.38 | −$1.82 |
| No. of analysts | 6 | 4 | 8 | 8 |
| Year-ago EPS | −$0.48 | −$0.38 | −$1.83 | — |
| Growth | +7.6% | −15.8% | +8.5% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $10000.00 | $5000.00 |
| Low estimate | $0.00 | $0.00 | $10000.00 | $5000.00 |
| High estimate | $0.00 | $0.00 | $10000.00 | $5000.00 |
| No. of analysts | 0 | 0 | 5 | 10 |
| Year-ago revenue | $0.00 | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Enliven Therapeutics, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AVBPArriVent BioPharma, Inc. Common Stock | Healthcare | Biotechnology | $563.8M | ||
| CGEMCullinan Therapeutics, Inc. | Healthcare | Biotechnology | $584.9M | ||
| EXELExelixis, Inc. | Healthcare | Biotechnology | $17.2B | ||
| INCYIncyte Corporation | Healthcare | Biotechnology | $24.0B | ||
| NUVBNuvation Bio Inc. | Healthcare | Biotechnology | $1.3B | ||
| ORICORIC Pharmaceuticals, Inc. | Healthcare | Biotechnology | $795.1M | ||
| RLAYRelay Therapeutics, Inc. | Healthcare | Biotechnology | $3.6B | ||
| RVMDRevolution Medicines, Inc. | Healthcare | Biotechnology | $34.6B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| RVXCFResverlogix Corp. | Healthcare | OTC | $23.0M | ||
| RXRXRecursion Pharmaceuticals, Inc. | Healthcare | NASDAQ | $1.8B | ||
| RYTMRhythm Pharmaceuticals, Inc. | Healthcare | NASDAQ | $8.3B | ||
| RZLTRezolute, Inc. | Healthcare | NASDAQ | $411.1M | ||
| SABSSAB Biotherapeutics, Inc. | Healthcare | NASDAQ | $288.3M | ||
| SABSWSAB Biotherapeutics, Inc. | Healthcare | NASDAQ | $10,514 | ||
| SANASana Biotechnology, Inc. | Healthcare | NASDAQ | $554.3M | ||
| SCNIScinai Immunotherapeutics Ltd. | Healthcare | NASDAQ | $189,871 | ||
| SCNLFScancell Holdings plc | Healthcare | OTC | $189.4M | ||
| SCPSScopus BioPharma Inc. | Healthcare | OTC | $16,833 | ||
| SCPXScorpius Holdings, Inc. | Healthcare | OTC | $130,071 | ||
| SCTXScribe Therapeutics Inc. | Healthcare | NASDAQ | $227.4M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.10% | |
| XSU.TOiShares U.S. Small Cap Index ETF (CAD-Hedged) | $627M in assets | 0.10% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.03% | |
| CANCTema Oncology ETF | $215M in assets | 3.06% | |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $516M in assets | 1.66% | |
| IHEiShares US Pharmaceuticals ETF | $1.7B in assets | 0.64% | |
| DWASInvesco Dorsey Wright SmallCap Momentum ETF | $376M in assets | 0.40% | |
Largest holders first, then the funds most concentrated in ELVN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Enliven Therapeutics, Inc., and how their positions are changing. At a $3.30B market value, institutional positions materially move Enliven Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Enliven Therapeutics, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Enliven Therapeutics, Inc.. Coverage tracks Enliven Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Enliven Therapeutics, Inc.